Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Multi-drug resistant nephrotic syndrome (MDR-NS) in children is associated with high morbidity and risk of progression to kidney failure. Low-density lipoprotein apheresis (LDL-A) has emerged as a potential adjunctive therapy, but data from developing countries remain scarce.
We conducted a prospective, single-arm, interventional study at a public-sector tertiary referral center over two years. Children <18 years with MDR-NS (eGFR >45 ml/min/1.73m²) or post-transplant focal segmental glomerulosclerosis (FSGS) recurrence refractory to plasma exchange and rituximab were enrolled. Each patient underwent 12 LDL-A sessions (double filtration or immunoadsorption) over nine weeks, in combination with corticosteroids and optimized immunosuppression. Clinical and laboratory parameters [urine protein–creatinine ratio (UPCR), serum albumin, lipid profile, and serum creatinine] were assessed at baseline, post-treatment, and during follow-up. Safety outcomes and adverse events were documented.
Ten children (median age 9.3 years, 7 males) received 11 cycles of LDL-A. Complete remission was observed in 4/11 at 1 month, 3/6 at 3 months, 3/5 at 6 months, and 1/2 at 12 months; partial remission occurred in 1/11 at 1 month and 1/5 at 6 months (median follow-up 4.5 months, IQR 8). LDL levels reduced by 50% post-treatment. No major procedure-related adverse events occurred; minor events included transient hypotension and hypocalcemia, managed conservatively. At 18 months, 1/2 patients with initial complete remission maintained sustained response.
LDL-apheresis appears safe and effective in inducing remission in children with MDR-NS and refractory post-transplant FSGS. Larger multicenter studies with longer follow-up are needed to validate efficacy and identify predictors of sustained remission.
